Reduced lipoxygenase and cyclooxygenase mediated signaling in PBMC of atopic dermatitis patients

Johanna Mihály, Janine Gericke, D. Törőcsik, Krisztián Gáspár, A. Szegedi, Ralph Rühl

Research output: Article

6 Citations (Scopus)

Abstract

Lipoxygenases (LOX) and cyclooxygenases (COX) are the main enzymes for poly-unsaturated fatty acid (PUFA) metabolism to highly bioactive prostaglandins, leukotrienes, thromboxanes and protectins. LOX and COX pathways are highly important for the regulation of pro-and anti-inflammatory active metabolite synthesis and metabolism in various inflammatory diseases like atopic diseases (AD). In this study using QRT-PCR, we found that in PBMCs the expression of 5-LOX, 12-LOX, 15-LOX and COX pathways and further enzymatic pathways like various leukotriene-hydoxylases, leukotriene-, prostaglandin-, and thromboxane-synthases as well as various of their membrane based receptors are mainly significantly down-regulated in AD-patients vs. healthy volunteers. In addition, using HPLC MS-MS we determined up to 19 different metabolites originating from eicosapentaenoic acid (EPA), docosapentaenoic acid (DHA) and arachidonic acid (AA) ranging from hydroxylated-PUFA derivatives and further bioactive derivatives like thromboxanes, leukotrienes, prostaglandins and protectins originating from LOX and COX metabolism. In PBMCs from AD-patients LOX and COX pathways were down-regulated. We conclude from this study, that in PBMCs from AD-patients in comparison to healthy volunteers, a systemic down-regulation of LOX-and COX-responses occurs to generally reduce eicosanoid/docosanoid synthesis during the current allergic inflammatory status.

Original languageEnglish
Pages (from-to)35-42
Number of pages8
JournalProstaglandins and Other Lipid Mediators
Volume107
DOIs
Publication statusPublished - 2013

Fingerprint

Lipoxygenases
Lipoxygenase
Atopic Dermatitis
Prostaglandin-Endoperoxide Synthases
Leukotrienes
Thromboxanes
CD59 Antigens
Metabolism
Polyunsaturated fatty acids
Prostaglandins
Metabolites
Unsaturated Fatty Acids
Arachidonate 12-Lipoxygenase
Arachidonate 15-Lipoxygenase
Healthy Volunteers
Derivatives
Arachidonate 5-Lipoxygenase
Eicosapentaenoic Acid
Eicosanoids
Arachidonic Acid

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Pharmacology
  • Cell Biology

Cite this

Reduced lipoxygenase and cyclooxygenase mediated signaling in PBMC of atopic dermatitis patients. / Mihály, Johanna; Gericke, Janine; Törőcsik, D.; Gáspár, Krisztián; Szegedi, A.; Rühl, Ralph.

In: Prostaglandins and Other Lipid Mediators, Vol. 107, 2013, p. 35-42.

Research output: Article

@article{779c3e1ed8da4bf2b48b63c2417dc25e,
title = "Reduced lipoxygenase and cyclooxygenase mediated signaling in PBMC of atopic dermatitis patients",
abstract = "Lipoxygenases (LOX) and cyclooxygenases (COX) are the main enzymes for poly-unsaturated fatty acid (PUFA) metabolism to highly bioactive prostaglandins, leukotrienes, thromboxanes and protectins. LOX and COX pathways are highly important for the regulation of pro-and anti-inflammatory active metabolite synthesis and metabolism in various inflammatory diseases like atopic diseases (AD). In this study using QRT-PCR, we found that in PBMCs the expression of 5-LOX, 12-LOX, 15-LOX and COX pathways and further enzymatic pathways like various leukotriene-hydoxylases, leukotriene-, prostaglandin-, and thromboxane-synthases as well as various of their membrane based receptors are mainly significantly down-regulated in AD-patients vs. healthy volunteers. In addition, using HPLC MS-MS we determined up to 19 different metabolites originating from eicosapentaenoic acid (EPA), docosapentaenoic acid (DHA) and arachidonic acid (AA) ranging from hydroxylated-PUFA derivatives and further bioactive derivatives like thromboxanes, leukotrienes, prostaglandins and protectins originating from LOX and COX metabolism. In PBMCs from AD-patients LOX and COX pathways were down-regulated. We conclude from this study, that in PBMCs from AD-patients in comparison to healthy volunteers, a systemic down-regulation of LOX-and COX-responses occurs to generally reduce eicosanoid/docosanoid synthesis during the current allergic inflammatory status.",
keywords = "Atopic dermatitis, Cyclooxygenase pathway, Lipoxygenese pathway, PBMC",
author = "Johanna Mih{\'a}ly and Janine Gericke and D. T{\"o}rőcsik and Kriszti{\'a}n G{\'a}sp{\'a}r and A. Szegedi and Ralph R{\"u}hl",
year = "2013",
doi = "10.1016/j.prostaglandins.2013.03.003",
language = "English",
volume = "107",
pages = "35--42",
journal = "Prostaglandins and Other Lipid Mediators",
issn = "0090-6980",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Reduced lipoxygenase and cyclooxygenase mediated signaling in PBMC of atopic dermatitis patients

AU - Mihály, Johanna

AU - Gericke, Janine

AU - Törőcsik, D.

AU - Gáspár, Krisztián

AU - Szegedi, A.

AU - Rühl, Ralph

PY - 2013

Y1 - 2013

N2 - Lipoxygenases (LOX) and cyclooxygenases (COX) are the main enzymes for poly-unsaturated fatty acid (PUFA) metabolism to highly bioactive prostaglandins, leukotrienes, thromboxanes and protectins. LOX and COX pathways are highly important for the regulation of pro-and anti-inflammatory active metabolite synthesis and metabolism in various inflammatory diseases like atopic diseases (AD). In this study using QRT-PCR, we found that in PBMCs the expression of 5-LOX, 12-LOX, 15-LOX and COX pathways and further enzymatic pathways like various leukotriene-hydoxylases, leukotriene-, prostaglandin-, and thromboxane-synthases as well as various of their membrane based receptors are mainly significantly down-regulated in AD-patients vs. healthy volunteers. In addition, using HPLC MS-MS we determined up to 19 different metabolites originating from eicosapentaenoic acid (EPA), docosapentaenoic acid (DHA) and arachidonic acid (AA) ranging from hydroxylated-PUFA derivatives and further bioactive derivatives like thromboxanes, leukotrienes, prostaglandins and protectins originating from LOX and COX metabolism. In PBMCs from AD-patients LOX and COX pathways were down-regulated. We conclude from this study, that in PBMCs from AD-patients in comparison to healthy volunteers, a systemic down-regulation of LOX-and COX-responses occurs to generally reduce eicosanoid/docosanoid synthesis during the current allergic inflammatory status.

AB - Lipoxygenases (LOX) and cyclooxygenases (COX) are the main enzymes for poly-unsaturated fatty acid (PUFA) metabolism to highly bioactive prostaglandins, leukotrienes, thromboxanes and protectins. LOX and COX pathways are highly important for the regulation of pro-and anti-inflammatory active metabolite synthesis and metabolism in various inflammatory diseases like atopic diseases (AD). In this study using QRT-PCR, we found that in PBMCs the expression of 5-LOX, 12-LOX, 15-LOX and COX pathways and further enzymatic pathways like various leukotriene-hydoxylases, leukotriene-, prostaglandin-, and thromboxane-synthases as well as various of their membrane based receptors are mainly significantly down-regulated in AD-patients vs. healthy volunteers. In addition, using HPLC MS-MS we determined up to 19 different metabolites originating from eicosapentaenoic acid (EPA), docosapentaenoic acid (DHA) and arachidonic acid (AA) ranging from hydroxylated-PUFA derivatives and further bioactive derivatives like thromboxanes, leukotrienes, prostaglandins and protectins originating from LOX and COX metabolism. In PBMCs from AD-patients LOX and COX pathways were down-regulated. We conclude from this study, that in PBMCs from AD-patients in comparison to healthy volunteers, a systemic down-regulation of LOX-and COX-responses occurs to generally reduce eicosanoid/docosanoid synthesis during the current allergic inflammatory status.

KW - Atopic dermatitis

KW - Cyclooxygenase pathway

KW - Lipoxygenese pathway

KW - PBMC

UR - http://www.scopus.com/inward/record.url?scp=84889099222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889099222&partnerID=8YFLogxK

U2 - 10.1016/j.prostaglandins.2013.03.003

DO - 10.1016/j.prostaglandins.2013.03.003

M3 - Article

VL - 107

SP - 35

EP - 42

JO - Prostaglandins and Other Lipid Mediators

JF - Prostaglandins and Other Lipid Mediators

SN - 0090-6980

ER -